Tarceva Sales Thrive at OSI

Last week, OSI Pharmaceuticals (Nasdaq: OSIP  ) reported a huge quarter that caught many investors by surprise. Total Q3 revenue for the company rose 77% year over year, topping Wall Street estimates by more than 15%. As a result, shares surged almost 14% on Friday.

Amazingly enough, there's room for further growth at OSI. The drugmaker announced 32% year-over-year improvement in worldwide net sales of the company's oncology drug, Tarceva, which it co-markets with Genentech (NYSE: DNA  ) and Roche. However, OSI noted that it experienced "unusually high" product returns in the U.S., related to expired inventory during Q3. This occurrence leads me to believe that the company could have more in store from Tarceva in subsequent quarters.

The rest of OSI's operations have continued in a healthy direction. The company saw a big spike in its license, milestone, and other revenue category. Key drivers of this advance included the amortization of an upfront license fee related to a licensing agreement granted to Eli Lilly (NYSE: LLY  ) , and license revenue tied to an agreement between Renovo and Shire (Nasdaq: SHPGY  ) . OSI also remains on track to complete the divestiture of its eye-disease business by the end of 2007. Once complete, it will mark the end of a short-lived venture which proved more of a hindrance than a help to the company's bottom line.

OSI really seems to have turned the corner since reporting a Q3 loss in 2006. In addition to the strong global sales improvement from Tarceva, and the exit from its eye disease business, OSI has an up-and-coming pipeline of drug candidates including PSN9301, a promising type 2 diabetes drug in phase 2 clinical trials.  Friday's results will likely bring about heightened expecations for OSI, but the company seems well-prepared for the challenge.

For more Foolishness check out:


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 539324, ~/Articles/ArticleHandler.aspx, 12/22/2014 4:16:45 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 17,804.80 26.65 0.15%
S&P 500 2,070.65 9.42 0.46%
NASD 4,765.38 16.98 0.36%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
OSIP.DL $0.00 Down +0.00 +0.00%
OSI Pharmaceutical… CAPS Rating: **
DNA $94.97 Down +0.00 +0.00%
Genentech, Inc. CAPS Rating: ****
LLY $72.40 Down -0.05 -0.07%
Eli Lilly & Co. CAPS Rating: ****
SHPG $216.73 Down -4.15 -1.88%
Shire plc (ADR) CAPS Rating: ****

Advertisement